Clinical trials
Axial Spondyloarthritis trials in the United States
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
33 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2009 | 1 |
| 2014 | 2 |
| 2015 | 6 |
| 2016 | 4 |
| 2017 | 1 |
| 2018 | 1 |
| 2019 | 4 |
| 2020 | 4 |
| 2021 | 1 |
| 2023 | 1 |
| 2024 | 1 |
| 2025 | 3 |
| 2026 | 4 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 15 |
| Terminated | 6 |
| Recruiting | 4 |
| Not yet recruiting | 3 |
| Unknown status | 2 |
| Withdrawn | 2 |
| Active, not recruiting | 1 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| UCB Biopharma SRL | 6 |
| UCB BIOSCIENCES, Inc. | 3 |
| CARE ARTHRITIS LTD. | 2 |
| Eli Lilly and Company | 2 |
| Janssen Research & Development, LLC | 2 |
| Novartis Pharmaceuticals | 2 |
| Oregon Health and Science University | 2 |
| The University of Texas Health Science Center, Houston | 2 |
| UCB BIOSCIENCES GmbH | 2 |
| AbbVie | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Axial Spondyloarthritis | 33 |
| Spondylitis, Ankylosing | 17 |
| Arthritis, Psoriatic | 9 |
| Arthritis, Rheumatoid | 6 |
| Crohn Disease | 5 |
| Non-Radiographic Axial Spondyloarthritis | 5 |
| Autoimmune Diseases | 3 |
| Spondylarthritis | 3 |
| Arthritis | 2 |
| Spinal Diseases | 2 |
Trials
Showing 1 to 25 of 33. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.